Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Core Insights - Xilio Therapeutics, Inc. is set to present late-breaking data on vilastobart, a tumor-activated anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025 [1] - The Phase 2 data will focus on the response rate of vilastobart in combination with atezolizumab for patients with microsatellite stable metastatic colorectal cancer and high plasma tumor mutational burden [1] Presentation Details - The abstract title for the presentation is "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer" [2] - The late-breaking abstract number is 1315, and the presentation is scheduled for November 7, 2025, from 9:00 a.m. to 7:00 p.m. EST at the Gaylord National Resort and Convention Center [2] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [3] - The company utilizes a proprietary platform to advance a pipeline of novel tumor-activated immuno-oncology molecules designed to enhance therapeutic efficacy within the tumor microenvironment [3]